SCUBE2 as a Marker of Resistance to Taxane-based Neoadjuvant Chemotherapy and a Potential Therapeutic Target in Breast Cancer
Objective:Taxane-based neoadjuvant chemotherapy is the most common neoadjuvant approach in breast cancer, especially in human epidermal growth factor receptor 2 (HER2)-positive and triple-negative subtypes. However, chemoresistance is a problem in many patients, and success rates are low in estrogen...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2023-01-01
|
| Series: | European Journal of Breast Health |
| Subjects: | |
| Online Access: |
http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/iscube2-i-as-a-marker-of-resistance-to-taxane-base/57736
|
| _version_ | 1797912425220014080 |
|---|---|
| author | Gülnihal Özcan |
| author_facet | Gülnihal Özcan |
| author_sort | Gülnihal Özcan |
| collection | DOAJ |
| description | Objective:Taxane-based neoadjuvant chemotherapy is the most common neoadjuvant approach in breast cancer, especially in human epidermal growth factor receptor 2 (HER2)-positive and triple-negative subtypes. However, chemoresistance is a problem in many patients, and success rates are low in estrogen receptor (ER)-positive breast cancer. The aim of this study was to identify predictive markers for resistance to taxane-based therapy, which may have a potential as therapeutic targets in breast cancer.Materials and Methods:Three comprehensive breast cancer Gene Expression Omnibus datasets were analyzed to identify differentially expressed genes (DEGs) in breast cancer patients resistant to taxane-based neoadjuvant chemotherapy. Functional annotation clustering and enrichment analysis were performed on the DEGs list. A protein-protein interaction network was established with the upregulated genes. The predictive value and the differential expression of the central genes were validated in the extensive ROC Plotter database.Results:Seventeen upregulated genes were found which were associated with resistance to taxane-based neoadjuvant therapy and high connectivity in the network analysis. ESR1, CCND1, and SCUBE2 emerged as the top three key genes associated with resistance. SCUBE2 displayed a high predictive power comparable to ESR1, and better than CCND1, the two commonly accepted markers. The predictive ability of SCUBE2 was higher in ER-positive and HER2-positive breast cancers.Conclusion:These results suggest that SCUBE2 may be used as a predictive marker to guide decisions on neoadjuvant therapy. Emerging evidence about the role of SCUBE2 as a coreceptor involved in tumor progression and angiogenesis also suggests SCUBE2 as a potential therapeutic target. These points should be investigated in further studies. |
| first_indexed | 2024-04-10T11:55:44Z |
| format | Article |
| id | doaj.art-46f64672ff634f59b58adbd4984e450f |
| institution | Directory Open Access Journal |
| issn | 2587-0831 |
| language | English |
| last_indexed | 2024-04-10T11:55:44Z |
| publishDate | 2023-01-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | European Journal of Breast Health |
| spelling | doaj.art-46f64672ff634f59b58adbd4984e450f2023-02-15T16:16:49ZengGalenos Publishing HouseEuropean Journal of Breast Health2587-08312023-01-01191455410.4274/ejbh.galenos.2022.2022-8-213049054SCUBE2 as a Marker of Resistance to Taxane-based Neoadjuvant Chemotherapy and a Potential Therapeutic Target in Breast CancerGülnihal Özcan0 Department of Medical Pharmacology, Koç University School of Medicine, İstanbul, Turkey Objective:Taxane-based neoadjuvant chemotherapy is the most common neoadjuvant approach in breast cancer, especially in human epidermal growth factor receptor 2 (HER2)-positive and triple-negative subtypes. However, chemoresistance is a problem in many patients, and success rates are low in estrogen receptor (ER)-positive breast cancer. The aim of this study was to identify predictive markers for resistance to taxane-based therapy, which may have a potential as therapeutic targets in breast cancer.Materials and Methods:Three comprehensive breast cancer Gene Expression Omnibus datasets were analyzed to identify differentially expressed genes (DEGs) in breast cancer patients resistant to taxane-based neoadjuvant chemotherapy. Functional annotation clustering and enrichment analysis were performed on the DEGs list. A protein-protein interaction network was established with the upregulated genes. The predictive value and the differential expression of the central genes were validated in the extensive ROC Plotter database.Results:Seventeen upregulated genes were found which were associated with resistance to taxane-based neoadjuvant therapy and high connectivity in the network analysis. ESR1, CCND1, and SCUBE2 emerged as the top three key genes associated with resistance. SCUBE2 displayed a high predictive power comparable to ESR1, and better than CCND1, the two commonly accepted markers. The predictive ability of SCUBE2 was higher in ER-positive and HER2-positive breast cancers.Conclusion:These results suggest that SCUBE2 may be used as a predictive marker to guide decisions on neoadjuvant therapy. Emerging evidence about the role of SCUBE2 as a coreceptor involved in tumor progression and angiogenesis also suggests SCUBE2 as a potential therapeutic target. These points should be investigated in further studies. http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/iscube2-i-as-a-marker-of-resistance-to-taxane-base/57736 breast cancerneoadjuvant chemotherapychemoresistancebiomarkersbioinformaticsscube2 |
| spellingShingle | Gülnihal Özcan SCUBE2 as a Marker of Resistance to Taxane-based Neoadjuvant Chemotherapy and a Potential Therapeutic Target in Breast Cancer European Journal of Breast Health breast cancer neoadjuvant chemotherapy chemoresistance biomarkers bioinformatics scube2 |
| title | SCUBE2 as a Marker of Resistance to Taxane-based Neoadjuvant Chemotherapy and a Potential Therapeutic Target in Breast Cancer |
| title_full | SCUBE2 as a Marker of Resistance to Taxane-based Neoadjuvant Chemotherapy and a Potential Therapeutic Target in Breast Cancer |
| title_fullStr | SCUBE2 as a Marker of Resistance to Taxane-based Neoadjuvant Chemotherapy and a Potential Therapeutic Target in Breast Cancer |
| title_full_unstemmed | SCUBE2 as a Marker of Resistance to Taxane-based Neoadjuvant Chemotherapy and a Potential Therapeutic Target in Breast Cancer |
| title_short | SCUBE2 as a Marker of Resistance to Taxane-based Neoadjuvant Chemotherapy and a Potential Therapeutic Target in Breast Cancer |
| title_sort | scube2 as a marker of resistance to taxane based neoadjuvant chemotherapy and a potential therapeutic target in breast cancer |
| topic | breast cancer neoadjuvant chemotherapy chemoresistance biomarkers bioinformatics scube2 |
| url |
http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/iscube2-i-as-a-marker-of-resistance-to-taxane-base/57736
|
| work_keys_str_mv | AT gulnihalozcan scube2asamarkerofresistancetotaxanebasedneoadjuvantchemotherapyandapotentialtherapeutictargetinbreastcancer |